Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 70 versus UROVIST SODIUM 300.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 70 versus UROVIST SODIUM 300.
OMNIPAQUE 70 vs UROVIST SODIUM 300
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast by increasing the density of blood vessels and organs.
Iodinated contrast agent that attenuates X-rays, improving visualization of vascular structures and organs during imaging.
1.5-2.0 mL/kg IV for contrast enhanced CT, max 150 mL; intra-arterial: 5-40 mL per injection depending on procedure.
Intravenous injection of 50-100 mL for contrast imaging, typically a single dose of 300 mg iodine/mL.
None Documented
None Documented
Terminal elimination half-life: 1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe dysfunction).
Terminal elimination half-life is approximately 2 hours in patients with normal renal function (GFR >90 mL/min). In renal impairment, half-life may be prolonged up to 10 hours or more, correlating with decreased GFR.
Renal: 100% unchanged via glomerular filtration. No biliary or fecal elimination.
Primarily renal (glomerular filtration), with >90% of the administered dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent